Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Estetrol,Drospirenone
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved
Recipient : Mithra Pharmaceuticals
Deal Size : $45.4 million
Deal Type : Licensing Agreement
Details : Under the agreements, Fuji Pharma obtains the rights to commercialize and advance the develoopment of Estelle, Mithra’s oral contraceptive product candidate based on Estetrol, for the treatment of Japanese patients with dysmenorrhea or endometriosis, i...
Brand Name : Estelle
Molecule Type : Small molecule
Upfront Cash : Undisclosed
October 23, 2023
Lead Product(s) : Estetrol,Drospirenone
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved
Recipient : Mithra Pharmaceuticals
Deal Size : $45.4 million
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?